Investopedia: Endo Health Solutions Needs Some Solutions Of Its Own

Running a specialty drug business is hard enough on its own - just ask Salix Pharmaceuticals (Nasdaq:SLXP), Forest Labs (NYSE:FRX) or Warner Chilcott (Nasdaq:WCRX) shareholders - but Endo Health Solutions (Nasdaq:ENDP) decided to up the difficulty level up going deeply into debt to fund a diversification into devices, services and medical records. With generics challenging the branded drug business and improvements needed in the AMS business, this is a tricky stock right now. Although Endo has a good history of generating solid free cash flow, I think investors are justified in questioning management's vision and this isn't an especially compelling stock today.

Please click here for more:
http://www.investopedia.com/stock-analysis/2012/Endo-Health-Solutions-Needs-Some-Solutions-Of-Its-Own-ENDP-JNJ-BCR-IPXL1107.aspx